Skip to main content

Table 1 Clinical profiles of the patients before SGLT-2 inhibitor administration

From: Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases

 

Case 1

Case 2

Case 3

Case 4

Case 5

Gender

Male

Male

Male

Male

Male

Age(years)

68

57

60

56

51

Primary renal disease

IgAN

IgAN

IgAN

DM

CGN

Period after

transplantation (years)

23.7

20.5

24.0

4.9

4.3

Waist circumference (cm)

92

104

91

94

112

Immunosuppressant

PSL, HCZ, CyA

MZB

PSL, CyA

MZB, EVR

PSL, CyA

MMF, EVR

PSL, TAC

MMF, EVR

PSL, TAC

MZB, EVR

Concomitant drugs

Febuxostat

Levothyroxine

Febuxostat

Fluvastatin

Cilnidipine

Valsartan

Febuxostat

Fluvastatin

Cilnidipine

Valsartan

Nifedipine

Valsartan

Dulaglutide

Insulin

degludec

Febuxostat

Fluvastatin

Ezetimibe

Complications

MetS, PTDM, HT HU, PsV, SAI

Hypothyroidism

MetS, HT,HU

Fatty liver

Dyslipidemia

MetS, HT, HU

Dyslipidemia

MetS, DM, HT

MetS, PTDM, HT

Dyslipidemia

C9 deficiency

Family

history

DM(-)

Renal disease(-)

DM(-)

Renal disease(-)

DM(-)

Renal disease(-)

DM(-)

Renal disease(-)

DM(-)

Renal disease(-)

Past

history

Pneumonia

10 times

Hopes zoster

Hypouricemia

None

Gastroduodenal

ulcer

  1. Abbreviations: BP blood pressure, CGN chronic glomerulonephritis, CyA cyclosporin A, DM diabetes mellitus, EVR everolimus, HCZ hydrocortisone, HT hypertension, HU Hyperuricemia IgAN IgA nephropathy, IGT impaired glucose tolerance, MetS metabolic syndrome, MMF mycophenolate mofetil, MZB mizoribine, PTDM post-transplant diabetes mellitus PsV psoriasis vulgaris, SAI secondary adrenal insufficiency, TAC tacrolimus